IMU 0.00% 10.5¢ imugene limited

News: Imugene progressing cancer vaccine towards clinical studies

  1. Imugene (ASX:IMU) is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine, a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.

    Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.

    It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.

    Charles Walker, managing director. outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.

    The full presentation can be ACCESSED HERE.

     

 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.000(0.00%)
Mkt cap ! $768.4M
Open High Low Value Volume
10.5¢ 10.8¢ 10.0¢ $746.7K 7.120M

Buyers (Bids)

No. Vol. Price($)
176 10004604 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 420568 8
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
10.3¢
  Change
0.000 ( 2.40 %)
Open High Low Volume
10.3¢ 10.5¢ 10.3¢ 1930285
Last updated 15.59pm 28/03/2024 ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.